Valeant Pharmaceuticals International, Inc. (VRX) - NYSE
  • Fri, Jun. 10, 12:30 PM
  • Thu, Jun. 9, 3:43 PM
    • Valeant Pharmaceuticals (VRX +5.2%) jumps on increased volume in response to the news that it is considering selling Egyptian drug maker Amoun Pharmaceutical in order to speed up its debt reduction. Goldman Sachs is advising.
    • Valeant acquired Amoun in July 2015 for ~$800M.
    • Previously: Valeant buys Amoun Pharma for $800M (July 17, 2015)
    | Thu, Jun. 9, 3:43 PM | 59 Comments
  • Thu, Jun. 9, 7:09 AM
    • Jaguar Animal Health (NASDAQ:JAGX) enters into a $15M 30-month common stock purchase agreement with Aspire Capital Fund, LLC. Upon the execution of the contract, Aspire bought 222,222 shares for $500K ($2.25/share). Remaining shares will be purchased at prevailing market prices.
    • The company and Napo Pharmaceuticals are involved in exploratory discussions about a possible merger and/or other ways to work together to build their businesses. Napo currently owns 26.3% of Jaguar common shares. Last month, it assumed ownership of the New Drug Application (NDA) and responsibility for human applications of crofelemer from Valeant Pharmaceuticals (NYSE:VRX) who acquired the rights from Salix Pharmaceuticals in April.
    • The FDA approved crofelemer, branded as Fulyzaq, in December 2012 for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on retroviral therapy.
    • JAGX closed yesterday at $1.32.
    | Thu, Jun. 9, 7:09 AM | 8 Comments
  • Tue, Jun. 7, 12:50 PM
    | Tue, Jun. 7, 12:50 PM | 5 Comments
  • Tue, Jun. 7, 11:00 AM
    | Tue, Jun. 7, 11:00 AM
  • Tue, Jun. 7, 9:29 AM
    • Embattled Valeant Pharmaceuticals (NYSE:VRX) hosted its Q1 earnings call this morning. New chief Joseph Papa and other executives discussed their plans to stabilize the business, pay down debt and ramp growth.
    • Q1 revenues were up 9.3% yoy but GAAP EPS dropped to a loss of $1.08 from a gain of $0.28. Cash flow from operations was $558M, up 13.6%. Non-GAAP EPS was $1.27, down 38.0% from Q1 2015's $2.05.
    • The biggest bogies are dermatology, accounting for $410M (37.3%) of the $1.1B downward revision in revenue guidance and liver drug Xifaxan (rifaximin), accounting for $390M (35.5%). The Walgreens deal is the main drag on dermatology sales. According to Mr. Papa, many prescriptions are currently being filled at a loss for Valeant.
    • The company says its will be in compliance with its debt covenants this year. It has $1.2B in cash at present and expects to generate $1.73B in free cash flow in 2016. It has $273M in mandatory debt payments for the remainder of the year. Its goal is to pay down $1.7B in debt by the end of December and have no more than a 6x leverage ratio.
    • Mr. Papa's plan to stabilize the business includes re-recruiting Valeant employees, adding new talent and buffing up its relationships with patients, prescribers, payors and investors. He is confident that he can fix the dermatology business and ramp Salix and Xifaxan sales growth. Over 20 new product launches are expected this year.
    | Tue, Jun. 7, 9:29 AM | 17 Comments
  • Tue, Jun. 7, 9:13 AM
    | Tue, Jun. 7, 9:13 AM
  • Tue, Jun. 7, 6:54 AM
    • Valeant Pharmaceuticals (VRX -0.1%) Q1 results: Revenues: $2,371.6M (+9.3%); R&D Expense: $103.1M (+84.8%); SG&A: $812.6M (+41.6%); Operating Income: $66.2M (-88.4%); Net Loss: ($373.7M); Loss Per Share: ($1.08); Non-GAAP EPS: $1.27 (-38.0%); Quick Assets: $1,310.4M (+119.4%); CF Ops: $558.1M (+13.6%).
    • 2016 Guidance: Total Revenue: $9.9B - 10.1B from $11.0B - 11.2B; Non-GAAP EPS: $6.60 - 7.00 from $8.50 - 9.50; Adjusted EBITDA: $4.80B - 4.95B from $5.60B - 5.80B.
    | Tue, Jun. 7, 6:54 AM | 40 Comments
  • Tue, Jun. 7, 6:03 AM
    • Valeant Pharmaceuticals (NYSE:VRX): Q1 EPS of $1.27 misses by $0.10.
    • Revenue of $2.37B (+9.2% Y/Y) misses by $10M.
    • Shares -3.95% PM.
    • Press Release
    | Tue, Jun. 7, 6:03 AM | 52 Comments
  • Tue, Jun. 7, 5:23 AM
    • Shall we try this again? Investors are hoping the sequel is better than the original when Valeant Pharmaceuticals (NYSE:VRX) posts its much-delayed Q1 results this morning.
    • The earnings report will be the second since a scandal last fall surrounding the drugmaker's relationship with mail-order pharmacy Philidor triggered a free fall in its stock. It will also be the first since new CEO Joseph Papa took over last month.
    • VRX +2% premarket
    | Tue, Jun. 7, 5:23 AM | 1 Comment
  • Mon, Jun. 6, 5:30 PM
    | Mon, Jun. 6, 5:30 PM | 22 Comments
  • Fri, Jun. 3, 7:37 AM
    • Bayer (OTCPK:BAYRY) and Espoo, Finland-based Orion expand their 2014 agreement to jointly develop BAY-1841788 (ODM-201) in prostate cancer, currently in Phase 3 development (ARAMIS study) for the treatment of high-risk non-metastatic castration-resistant prostate cancer.
    • The new indication will be for the treatment of newly diagnosed metastatic hormone-sensitive prostate cancer, in combination with docetaxel, in men who are starting first-line hormone therapy.
    • A Phase 3 study, called ARASENS, will begin enrolling patients in late Q4. The double-blind, placebo-controlled trial will randomize ~1,300 subjects 1:1 to receive either BAY-1841788 (ODM-201) or placebo in combination with an androgen deprivation therapy of the investigator's choice started no more than 12 weeks before randomization. The primary endpoint is overall survival.
    • BAY-1841788 is an oral androgen receptor antagonist.
    • Prostate cancer-related tickers: (NASDAQ:MDVN)(OTCPK:ALPMY)(NYSE:VRX)(NASDAQ:TTHI)(NASDAQ:EDAP)(NASDAQ:TKAI)(NYSE:JNJ)(NASDAQ:TSRO)(NYSE:AZN)(NASDAQ:EGRX)(NASDAQ:OGXI)
    | Fri, Jun. 3, 7:37 AM
  • Tue, May 31, 6:22 PM
    • Valeant Pharmaceuticals (NYSE:VRX) sets June 7 at 8:00 am ET for its conference call to discuss Q1 results. Consensus view is EPS of $1.38 on revenues of $2.39B.
    | Tue, May 31, 6:22 PM | 76 Comments
  • Tue, May 31, 9:23 AM
    • In a regulatory filing, Valeant Pharmaceuticals (NYSE:VRX) discloses the details of its Separation Agreement with former chief Micheal Pearson. In exchange for a general release of claims, Mr. Pearson will receive a severance payment of $9M and the continuation of medical coverage for two years. He will also be required to hold the 1M shares of common stock he received in the settlement of his equity awards for two years.
    • Pearson will provide consulting services through December 2017 subject to one-month renewals after 2017. He will receive $83,333 per month through the end of this year and $15,000 per month thereafter. The company will provide him with office space and nonexclusive access to an administrative assistant and IT support for two years.
    | Tue, May 31, 9:23 AM | 71 Comments
  • Fri, May 27, 11:00 AM
    | Fri, May 27, 11:00 AM
  • Fri, May 27, 9:12 AM
    | Fri, May 27, 9:12 AM
Company Description
Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical company that develops manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics. The company operates through two... More
Sector: Healthcare
Industry: Drug Delivery & Accessories
Country: Canada